Navigation Links
Laureate Pharma Announces New Development and Manufacturing Agreement to Produce AVEO Pharmaceuticals' Antibody Therapeutic

PRINCETON, N.J., Oct. 27 /PRNewswire/ -- Laureate Pharma, Inc., a full-service contract development and manufacturing organization, announced today that they have entered into a development and manufacturing agreement to produce AV-203, AVEO Pharmaceutical's (Cambridge, MA) novel monoclonal antibody targeted against ErbB3.  Laureate's services will include process development, protein production, purification and aseptic filling of AP-203 for AVEO.  The project is presently underway and Laureate expects to supply AVEO with clinical product in the second quarter of 2011.  Terms of the manufacturing agreement were not disclosed.

"AVEO has a very impressive pipeline of monoclonal antibody-based products for treatment of cancer and we are pleased to work with them on this exciting antibody product," said Steve Johnson, Vice President, Business Development, of Laureate Pharma.  "We look forward to a productive and successful relationship with AVEO to provide clinical supply of their monoclonal antibodies."

AV-203 is an ErbB3 (HER3)-targeted antibody. ErbB3 belongs to a family of four proteins that also includes the epidermal growth factor receptor (EGFR) and the HER2 receptor. Both EGFR and HER2 have been implicated in promoting the growth of significant numbers of tumors, particularly in breast and lung cancers. Drugs blocking the activity of EGFR have demonstrated clinical benefit in lung, colon and head and neck cancers, while drugs targeting HER2 show clinical benefit in the treatment of HER2 over-expressing breast cancers. ErbB3 is significantly over-expressed in many human breast, ovarian, prostate, colorectal, pancreatic, gastric, and head and neck cancers, which generally correlates with poor prognosis.

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical contract development and manufacturing organization. Laureate's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.  

About Saints Capital, LLC.

Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit

For more information, contact Steve Johnson, Vice President, Business Development or Imara Charles, Ph.D., Director of Project Management at (609) 919-3400,,       or Jennifer Vollaro at Integrated Marketing Services at (609) 683-9055 ext. 247,

SOURCE Laureate Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Elsevier Celebrates Nine 2010 Nobel Laureates and Honors Achievements With Freely Available Prize-Winning Research
2. Laureate Pharma Secures $20 Million to Enhance and Grow Biopharmaceutical Contract Manufacturing Business
3. Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development
4. Thomson Reuters Predicts Nobel Laureates
5. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
6. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
7. As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies Needed
8. Essential Pharmaceuticals Acquires Exclusive Worldwide Rights to Family of Cell Media Products from Lifeblood Medical
9. Teva Pharmaceuticals and the Philadelphia Eagles Award Four Grants to Greater Philadelphia Area Service Organizations
10. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
11. CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
Breaking Medicine Technology:
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):